AI Just Made Drug Discovery 1,000,000x Faster
Why It Matters
By delivering drug‑candidate quality peptides at unprecedented speed, LiganForge could dramatically shorten development timelines and lower costs across the $50 billion peptide market.
Key Takeaways
- •Peptide market exceeds $50 billion, but discovery remains ultra‑complex.
- •LiganForge generates 700 peptide designs per second on one GPU.
- •Speed outpaces competitors: 10k× Bolts Gen, >1 M× Bind Craft by margin.
- •Produced nanomolar‑strength binders for five toughest targets in minutes.
- •Traditional AI tools failed where LiganForge succeeded across all targets.
Summary
The video announces LiganForge, a new AI platform that accelerates peptide drug design by bypassing traditional 3‑D shape prediction.
With the peptide market now over $50 billion, the combinatorial space—10 positions × 20 amino acids—exceeds 10 trillion possibilities, making conventional discovery painstaking. Existing tools such as Bind Craft and Bolts Gen generate a few hundred candidates per day by first modeling structure then screening.
LiganForge replaces the two‑step workflow with a single forward pass, delivering roughly 700 sequences per second on a single GPU—10,000× faster than Bolts Gen and over a million times faster than Bind Craft. In a benchmark against five of the most challenging therapeutic targets, it produced 150,000 candidates in 3.4 minutes, achieving predicted binding affinities in the low‑nanomolar range, whereas Bolts Gen succeeded on only one target and Bind Craft on none.
If the predictions hold up experimentally, the platform could compress years of laboratory work into hours, slashing R&D costs and reshaping competitive dynamics in peptide therapeutics.
Comments
Want to join the conversation?
Loading comments...